Biolinerx Ltd., of Jerusalem, reported final results from the phase I/II study of BL-7010, showing the co-polymer, designed to treat celiac disease, was safe and well-tolerated in single- and repeated-dose administrations. Pharmacokinetic analyses across all cohorts revealed no systemic exposure of BL-7010 in plasma and urine samples. The study also enabled the company to determine the optimal safe dose of 1 gm, three times daily, for future development.